Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Comment by NEMOMEIMPUNEon Jul 16, 2021 9:24am
202 Views
Post# 33558483

RE:RE:RE:Don't bother about the rudiment buying...

RE:RE:RE:Don't bother about the rudiment buying...Yes Johnmeco,

Following info was given i the end of may.
They have not commented on this so far, but I think the first dollars has already found its way to WAVE and they will have something to tell us in august.
Remember there is an enormous backlog with patients with cancer i Enland (for surgery)...so what to do other than give them medicine. And that is not in the prognosis of amounts of vials in the text below.
I'm not ready with my buying, so please don't push the price to far up.
Sorry for bad spelling... I'm a swedish moron ..you know !  ;) 

Best from Sweden,
NEMO
.............................................................
WINNIPEG, MB, May 27, 2021 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), a Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited ("WPEL"), has been awarded exclusive distribution rights for two strengths of pemetrexed (100mg and 500mg) by the National Health Service of England ("NHS England") for the Central and South West Region of England. The awarded NHS England tender is the Company's first awarded tender for pemetrexed in the United Kingdom ("UK"). The awarded tender has the following projected annual supply quantities based on the award debrief provided by NHS England: pemetrexed 100mg – 10,500 vials pemetrexed 500mg – 9,300 vials The tender will commence on June 15, 2021 and has a duration of 12.5 months. WPEL continues to apply for additional tenders in the UK and across the European Union ("EU") for pemetrexed and hopes to further increase its presence across Europe. "Waverley Pharma is pleased to announce our first awarded pemetrexed tender in the UK, adding to the continued growth of our oncology presence in this market" stated Larry Thiessen, President and Chief Executive Officer.
<< Previous
Bullboard Posts
Next >>